Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Tara C Mitchell"'
Autor:
Omid Hamid, Diwakar Davar, Keisuke Shirai, Benjamin Izar, Charlotte E Ariyan, Michael K Wong, Jason J Luke, Janis M Taube, Anna C Pavlick, Meghan J Mooradian, Douglas B Johnson, Hussein A Tawbi, Tara C Mitchell, Ryan J Sullivan, April KS Salama, Krista M Rubin, Elizabeth I Buchbinder, Sarah A Weiss, Tina J Hieken, Geoffrey T Gibney, Rajan P Kulkarni, J Keith Tolley, Caressa Valdueza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regi
Externí odkaz:
https://doaj.org/article/f4721e0504094c6083b6710589696855
Autor:
Alexander Huang, Jeffrey C Thompson, Christiana Davis, Charuhas Deshpande, Wei-Ting Hwang, Seth Jeffries, Tara C Mitchell, Corey J Langer, Steven M Albelda
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Limited data exist on the role of alterations in HLA Class I antigen processing and presentation machinery in mediating response to immune checkpoint blockade (ICB).Methods This retrospective cohort study analyzed transcriptional profiles
Externí odkaz:
https://doaj.org/article/ee688b09a74b4b888bc01809fd2a86d6
Autor:
Lei Guan, Bin Wu, Ting Li, Lynn A. Beer, Gaurav Sharma, Mingyue Li, Chin Nien Lee, Shujing Liu, Changsong Yang, Lili Huang, Dennie T. Frederick, Genevieve M. Boland, Guangcan Shao, Tatyana M. Svitkina, Kathy Q. Cai, Fangping Chen, Meng-Qiu Dong, Gordon B. Mills, Lynn M. Schuchter, Giorgos C. Karakousis, Tara C. Mitchell, Keith T. Flaherty, David W. Speicher, Youhai H. Chen, Meenhard Herlyn, Ravi K. Amaravadi, Xiaowei Xu, Wei Guo
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Lack of CD8+ T-cell infiltration into solid tumors is associated with poor responsiveness to immune checkpoint therapy (ICT). Here, the authors show that blocking the phosphorylation of HRS to reduce the induction of immunosuppressive exosomes promot
Externí odkaz:
https://doaj.org/article/718e304323ab40bb82fc54fc7895e125
Autor:
Geoffrey T. Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas F. Gajewski, Bartosz Chmielowski, Brent A. Hanks, Yufan Zhao, Robert C. Newton, Janet Maleski, Lance Leopold, Jeffrey S. Weber
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-
Externí odkaz:
https://doaj.org/article/5099b0af01e64192a7b84fc9a960caa6
Autor:
Payal D. Shah, Alexander C. Huang, Xiaowei Xu, Robert Orlowski, Ravi K. Amaravadi, Lynn M. Schuchter, Paul Zhang, Julia Tchou, Tina Matlawski, Amanda Cervini, Joanne Shea, Joan Gilmore, Lester Lledo, Karen Dengel, Amy Marshall, E. John Wherry, Gerald P. Linette, Andrea Brennan, Vanessa Gonzalez, Irina Kulikovskaya, Simon F. Lacey, Gabriela Plesa, Carl H. June, Robert H. Vonderheide, Tara C. Mitchell
Publikováno v:
Cancer Research Communications. 3:821-829
Purpose: Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC). This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0368480eb756635728b862b5d77d081c
https://doi.org/10.1158/2767-9764.crc-22-0486
https://doi.org/10.1158/2767-9764.crc-22-0486
Autor:
Cimarron E, Sharon, Richard J, Straker, Phyllis A, Gimotty, Emily Y, Chu, Tara C, Mitchell, John T, Miura, Michael A, Marchetti, Edmund K, Bartlett, Giorgos C, Karakousis
Publikováno v:
Journal of the American Academy of Dermatology. 88:802-807
Given the results of the recent KEYNOTE-716 trial, the performance of sentinel lymph node (SLN) biopsy for patients with clinical stage IIB/C melanoma has been questioned.Determine the utility of SLN status in guiding the recommendations for adjuvant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bd5aa47dd3f4bd0f31bf38348820ae8
https://doi.org/10.1016/j.jaad.2022.11.033
https://doi.org/10.1016/j.jaad.2022.11.033
Autor:
Josephine R. Giles, Shin Foong Ngiow, Sasikanth Manne, Amy E. Baxter, Omar Khan, Ping Wang, Ryan Staupe, Mohamed S. Abdel-Hakeem, Hua Huang, Divij Mathew, Mark M. Painter, Jennifer E. Wu, Yinghui Jane Huang, Rishi R. Goel, Patrick K. Yan, Giorgos C. Karakousis, Xiaowei Xu, Tara C. Mitchell, Alexander C. Huang, E. John Wherry
Publikováno v:
Nature Immunology. 23:1600-1613
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::277752491a42aa61ea5003f33b68b30f
https://doi.org/10.1038/s41590-022-01338-4
https://doi.org/10.1038/s41590-022-01338-4
Autor:
Ramin Sedaghat Herati, David A. Knorr, Laura A. Vella, Luisa Victoria Silva, Lakshmi Chilukuri, Sokratis A. Apostolidis, Alexander C. Huang, Alexander Muselman, Sasikanth Manne, Oliva Kuthuru, Ryan P. Staupe, Sharon A. Adamski, Senthil Kannan, Raj K. Kurupati, Hildegund C. J. Ertl, Jeffrey L. Wong, Stylianos Bournazos, Suzanne McGettigan, Lynn M. Schuchter, Ritesh R. Kotecha, Samuel A. Funt, Martin H. Voss, Robert J. Motzer, Chung-Han Lee, Dean F. Bajorin, Tara C. Mitchell, Jeffrey V. Ravetch, E. John Wherry
Publikováno v:
Nature Immunology. 23:1183-1192
Anti-programmed death-1 (anti-PD-1) immunotherapy reinvigorates CD8 T cell responses in patients with cancer but PD-1 is also expressed by other immune cells, including follicular helper CD4 T cells (Tfh) which are involved in germinal centre respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfacb13b0f2528653066d1f057ca5249
https://doi.org/10.1038/s41590-022-01274-3
https://doi.org/10.1038/s41590-022-01274-3
Autor:
Emily J Anstadt, Brian Chu, Nikhil Yegya-Raman, Xiaoyan Han, Abigail Doucette, Kendra Poirier, Jahan J Mohiuddin, Amit Maity, Andrea Facciabene, Ravi K Amaravadi, Giorgos C Karakousis, Justine V Cohen, Tara C Mitchell, Lynn M Schuchter, John N Lukens
Publikováno v:
The Oncologist. 27:799-808
Background For patients with melanoma, gastrointestinal immune-related adverse events are common after receipt of anti-CTLA4 therapy. These present difficult decision points regarding whether to discontinue therapy. Detailing the situations in which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e29e81bd86f84af8444113e548e39a
https://doi.org/10.1093/oncolo/oyac108
https://doi.org/10.1093/oncolo/oyac108
Autor:
Tara C. Mitchell, Robert H. Vonderheide, Carl H. June, Gabriela Plesa, Simon F. Lacey, Irina Kulikovskaya, Vanessa Gonzalez, Andrea Brennan, Gerald P. Linette, E. John Wherry, Amy Marshall, Karen Dengel, Lester Lledo, Joan Gilmore, Joanne Shea, Amanda Cervini, Tina Matlawski, Julia Tchou, Paul Zhang, Lynn M. Schuchter, Ravi K. Amaravadi, Robert Orlowski, Xiaowei Xu, Alexander C. Huang, Payal D. Shah
Study procedures. Participant study procedures including cell collection/manufacturing timeline as well as infusion schedule from eligibility confirmation onward.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04e40732ed1e1a9fe11f9fc7a214caad
https://doi.org/10.1158/2767-9764.22787708.v1
https://doi.org/10.1158/2767-9764.22787708.v1
